Horizon Therapeutics PLC (NASDAQ:HZNP) CFO Paul W. Hoelscher sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $28.01, for a total transaction of $560,200.00. Following the sale, the chief financial officer now directly owns 149,310 shares in the company, valued at approximately $4,182,173.10. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
Paul W. Hoelscher also recently made the following trade(s):
- On Wednesday, August 21st, Paul W. Hoelscher sold 70,903 shares of Horizon Therapeutics stock. The stock was sold at an average price of $28.00, for a total transaction of $1,985,284.00.
Shares of NASDAQ:HZNP opened at $27.40 on Friday. Horizon Therapeutics PLC has a 1 year low of $16.56 and a 1 year high of $29.44. The firm has a market capitalization of $5.31 billion, a price-to-earnings ratio of 14.97, a price-to-earnings-growth ratio of 1.68 and a beta of 0.83. The company has a debt-to-equity ratio of 0.90, a current ratio of 2.20 and a quick ratio of 2.12. The business’s 50 day moving average price is $26.96 and its 200-day moving average price is $25.71.
Horizon Therapeutics (NASDAQ:HZNP) last announced its earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.14. Horizon Therapeutics had a return on equity of 30.33% and a net margin of 5.90%. The firm had revenue of $320.60 million for the quarter, compared to analyst estimates of $296.27 million. During the same quarter last year, the firm posted $0.48 EPS. The business’s revenue was up 5.9% on a year-over-year basis. On average, sell-side analysts expect that Horizon Therapeutics PLC will post 1.59 earnings per share for the current year.
A number of equities research analysts have recently commented on the stock. Stifel Nicolaus set a $35.00 price objective on shares of Horizon Therapeutics and gave the stock a “buy” rating in a research note on Friday, September 13th. Guggenheim assumed coverage on shares of Horizon Therapeutics in a research note on Thursday, September 12th. They set a “buy” rating and a $36.00 price objective on the stock. ValuEngine cut shares of Horizon Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, September 5th. Bank of America assumed coverage on shares of Horizon Therapeutics in a research note on Thursday, September 26th. They set a “buy” rating and a $34.00 price objective on the stock. Finally, BidaskClub cut shares of Horizon Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, September 6th. Four analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $33.67.
Several large investors have recently made changes to their positions in HZNP. New York State Teachers Retirement System purchased a new position in shares of Horizon Therapeutics during the 2nd quarter valued at approximately $55,000. Steward Partners Investment Advisory LLC purchased a new position in Horizon Therapeutics in the 2nd quarter valued at $76,000. FNY Investment Advisers LLC purchased a new position in Horizon Therapeutics in the 2nd quarter valued at $80,000. Tower Research Capital LLC TRC lifted its holdings in Horizon Therapeutics by 384.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,389 shares of the biopharmaceutical company’s stock valued at $82,000 after purchasing an additional 2,689 shares in the last quarter. Finally, Advisory Services Network LLC lifted its holdings in Horizon Therapeutics by 1,100.3% in the 2nd quarter. Advisory Services Network LLC now owns 3,469 shares of the biopharmaceutical company’s stock valued at $83,000 after purchasing an additional 3,180 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.
About Horizon Therapeutics
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
Recommended Story: Most Volatile Stocks
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.